7,436.25

+34.25

+0.46%

51,772.00

+387.00

+0.75%

27,171.75

+86.50

+0.32%

Russell 2000 Futures

2,791.10

+30.60

+1.11%

4.8590

+0.0220

+0.45%

23.57

-2.07

-8.08%

4,105.50

+30.60

+0.75%

74,043.05

-1,743.38

-2.30%

Crude Oil Dec 26

89.97

-0.86

-0.95%

US Private Equity

10,772.76

+11.83

+0.11%

NasdaqCM - Nasdaq Real Time Price USD

Outlook Therapeutics, Inc. (OTLK)

0.4364 -0.0027 (-0.61%)

At close: November 6 at 4:00:01 PM EST

0.4500 +0.0136 (+3.12%)

Pre-Market: 5:35:31 AM EST

Loading Chart for OTLK

Chart Range Bar

Interval:

In partnership with ChartIQ

Outlook Therapeutics Names Greg DiPasquale Chief Commercial Officer

Outlook Therapeutics Names Greg DiPasquale Chief Commercial Officer

Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand

Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand

Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™

Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™

Outlook Therapeutics (OTLK) Stock May Be No Bargain With Approval But Weak Balance Sheet

Outlook Therapeutics (OTLK) Stock May Be No Bargain With Approval But Weak Balance Sheet

Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™

Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™

Why Did OTLK Stock Crash In Pre-Market Today?

Why Did OTLK Stock Crash In Pre-Market Today?

Outlook Therapeutics Announces Proposed Public Offering of Common Stock and Warrants

Outlook Therapeutics Announces Proposed Public Offering of Common Stock and Warrants

Outlook Therapeutics to Report Third Quarter Fiscal Year 2026 Financial Results and Host a Corporate Update Conference Call and Webcast on August 14, 2026

Outlook Therapeutics to Report Third Quarter Fiscal Year 2026 Financial Results and Host a Corporate Update Conference Call and Webcast on August 14, 2026

Outlook Therapeutics to Report Q3 Earnings: What's in the Cards?

Outlook Therapeutics to Report Q3 Earnings: What's in the Cards?

Outlook Therapeutics’ Recently Approved Therapy Could Become Preferred Anti-VEGF Treatment Option In $8.5B US Retina Market, Says BTIG

Outlook Therapeutics’ Recently Approved Therapy Could Become Preferred Anti-VEGF Treatment Option In $8.5B US Retina Market, Says BTIG

Outlook Therapeutics wins FDA approval for Lytenava in wet AMD

Outlook Therapeutics wins FDA approval for Lytenava in wet AMD

Mobilize your Website

View Site in Mobile | Classic

Share by: